From Patient Registry to a International Scientific Conference
Our study on NF1-associated gastrointestinal stromal tumors was accepted for presentation at ASCO this year - this milestones highlights the power of patient registries.
LRG & Collaborators Publish New Paper on Adjuvant Imatinib in KIT Exon 9 Mutations
Published on February 26, 2026, this international study represents a major collaboration between The Life Raft Group and thirty-five leading cancer centers across the U.S., Europe, and Japan to better understand treatment for gastrointestinal stromal tumors (GIST) with KIT exon 9 mutations.
Patient Perspective on Testing – Survey Highlights
Survey highlights show that most GIST patients receive mutational testing, but awareness of ctDNA testing remains low despite strong interest.
Understanding Genomic Testing and SDH-Deficiency in Gastrointestinal Stromal Tumors (GISTs)
Understand why genetic testing is crucial for identifying and managing SDH-deficient GISTs, a rare and often hereditary tumor that requires specialized care.
New Collaborative Study on Genomic Testing in SDH‐Deficienct GIST
The LRG and the Pediatric & SDH-Deficient GIST Consortium published a paper this February on Genomic Testing in SDH-deficient GIST.
ESMO 2024 Summary
ESMO 2024 Summary
New Clinical Trials Focus for the LRG in 2024
Starting in January, every Wednesday will be dedicated learning about clinical trial process and to highlighting the groundbreaking clinical trials focused on gastrointestinal stromal tumors (GIST).
New Life Raft Group Paper Published
The LRG publishes, "Gastrointestinal Stromal Tumor Patients with Molecular Testing Exhibit Superior Survival Compared to Patients without Testing: Results from the Life Raft Group (LRG) Registry" Cancer Investigation ,Vol. 41, 2023. Issue 5 [...]
Progress in Precision Medicine for GIST Patients
These new data were presented by Dr. Sebastian Bauer and Dr. Breelyn A. Wilky during the 2023 January ASCO Plenary Series from the INTRIGUE Efficacy Results of ctDNA Analysis for GIST Patients.
Collaborative Effort Produces Position Paper on Need for Advanced Biomarker Testing
The Life Raft Group was recently part of team of authors on a collaborative position paper entitled 'Undetected KIT and PDGFRA mutations: an under-recognised cause of gastrointestinal stromal tumours (GISTs) incorrectly classified as wild-type published' in Pathology: The Journal of the Royal College of Pathologists of Australia.